Peripheral artery disease (PAD) is estimated to affect 27 million individuals in Europe and North
America and its prevalence is increasing in concert with recent demographic and risk factor trends. 1 The majority of patients with PAD are either asymptomatic or have atypical leg symptoms, with classical claudication in only 10-35%, therefore detection is elusive unless actively sought. 2 Given shared risk factors, it is axiomatic that there exists a high co-prevalence of atherosclerosis in other vascular beds including the coronary arteries in PAD patients.
However, PAD disproportionately affects the elderly, non-whites, and women compared with CAD alone. 3, 4 The actual co-prevalence of CAD in patients with established PAD depends on how closely it is searched for, with clinical history and ECG detecting only 20-40% of coexisting disease whereas cardiac catheterization detects CAD in as many as 90% of PAD patients. 5, 6 There is a direct relationship between the severity of PAD (e.g. as measured by the anklebrachial index) and cardiovascular and overall mortality, regardless of whether the PAD is symptomatic or not. 7, 8 In general, men and women with PAD have about a 5-fold greater risk of cardiovascular mortality and a 3-fold greater risk for all-cause mortality even after adjusting for known Framingham risk factors. 9 Patients with PAD have worse outcomes following acute ischemic events and hospitalizations for acute coronary syndrome and after percutaneous coronary interventions. 1, 10 Current guidelines for secondary prevention and risk reduction therapy in patients with PAD recommend anti-platelet therapy, lipid-lowering therapy with a statin to achieve a goal low density lipoprotein (LDL) < 100 mg/dl (or <70 mg/dl in high-risk patients), and antihypertensive therapy to achieve a systolic blood pressure < 140 mmHg (or < 130 mmHg in diabetics and chronic renal disease). 2, 11 Despite these guidelines cross sectional studies, registries, and surveys existing disease whereas cardiac catheterization detects CAD in as many as 90% % % of of f P PAD AD AD patients. 5, 6 Th Th Ther er e e e is a a a d d dir i ect relationship between the e e s se everity of PAD D D (e.g g. . a as as measured by the ankleb br rac c chi h al index x) ) a a and d d ca ca ard rd dio io iova va vasc sc scul ular ar ar a a and nd d o o over ra al ll l mo or ort tali ity ty ty, , re re ega a ard rdl l les s ss o of f f w whe heth th the er er t the he he P P PAD AD A i i is s f f f y ymp mp mpto to toma mati ti tic c c or or n n no ot ot. 7, 7, 8 8 I In n ge gen ne nera ra al l l, m m men en n a a and nd nd w w wom om ome en en w wi it ith h h PA PA PAD D D ha ha ave ve e a a abo bo ou ut ut a a 5 5 5-f -f fol old d d g gr grea a ate e er r ri ris sk sk o of cardiovascul lar ar ar m m mor or orta ta tali li ity ty y and nd nd a a 3 3 3-f -f fol ol ld d d gr gr grea ea ate te ter r r ri ri r sk sk sk fo fo for r r al all-l-l ca ca caus us use e e mo mo m rt rt tal al alit it ity y y ev ev even en e a a aft ft fter er er a a adj dj d usting for have consistently shown that utilization of proven cardioprotective medication for secondary prevention in patients with PAD significantly lags behind CAD. 12, 13 The reasons behind this gap in treatment aggressiveness for atherosclerosis in the periphery remain unclear. Cross sectional "snapshots" are limited by lacking incidence data, incomplete assessment of medication compliance, and inability to capture practice trends over time. Importantly, they also fail to provide information on the impact of the incident diagnosis of PAD on subsequent medical management, reflecting the treating physician's awareness and attitudes toward PAD and its treatment. It is here that the current report by Subherwal and colleagues of a longitudinal, population-based cohort study conducted in Denmark has given us a valuable insight. with PAD alone, combined PAD and CAD, and CAD alone.
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http://circ.ahajournals.org/ Downloaded from study period with a doubling in the use of anti-platelet agents and a 6-fold increase in the use of statins for the PAD alone group. After the diagnosis of PAD or CAD was made and the physician became aware of the disease, there was also an improvement of cardioprotective medications. However the improvement was far less in both PAD subgroups compared with the CAD alone group. For all PAD patients, 41.9% were on antiplatelet therapy prior to diagnosis increasing to just 48.3% within the first 3 months subsequent to making a diagnosis of PAD.
Statin use was also low, though increasing from 27.6% to 36.9% following the diagnosis of PAD. One of the most startling observations was that the publication of PAD guidelines in 2005
made an almost imperceptible difference in the temporal prescribing patterns, suggesting that their impact was modest.
One might presume that the newly diagnosed patients in the Denmark cohort had mild PAD and therefore the diagnosing physicians were less likely to prescribe medications.
However, examining results of recently completed surgery trials suggests otherwise. The PREVENT III study, which was the largest prospective North American trial conducted in patients undergoing lower extremity bypass surgery for critical limb ischemia, suggests that even the most vulnerable patients are undertreated. 15 In this study there was an improvement of aspirin therapy from the time of admission at 67% to 88% by the time of discharge following leg bypass surgery. Similar trends were also noted for -blockers, 49% on admission to 60% at the time of discharge while statin usage was stable at 46% throughout the hospitalization. One of the salient findings from the PREVENT III study was that both racial and practice setting patients under er rgo go goin in ng g g lo lo owe w w r r ex ex extr t t em em emit ity y y by y ypa pa pass ss ss s s sur ur urge ge gery ry ry f fo or r r cr cr crit it itic ic ical al al l l lim im imb b b is is isch ch chem em emia ia, , su su sugg gg gges es e ts that even n n United Kingdom-based study comparing angioplasty-first to bypass surgery-first in patients with severe limb ischemia, aspirin and statin use were 54% and 34% respectively. 16 So even patients requiring surgical or endovascular interventions for advanced limb ischemia, in both Europe and the United States, are not receiving medical therapies within guidelines.
In general, all 3 Danish subgroups examined by Subherwal et al are out of compliance with evidenced-based, secondary prevention medications. The group with clinically evident PAD and CAD, a particularly vulnerable group with polyvascular disease, had just 65% antiplatelet and 48.3% statin usage 3 months after incident diagnosis. It is reasonable to assume similar patterns of compliance in other affluent countries and far inferior compliance in lower income countries, particularly in their rural areas. 17 Hence, underutilization of cardioprotective medication in patients with PAD is a conspicuous example of a more generalized failure to embrace secondary preventive guidelines.
Cardiovascular practice guidelines for secondary prevention are designed to support decision making processes to achieve treatment goals of blood pressure and lipid levels, and are ultimately aimed towards improving outcomes and quality of care. However considerable clinical inertia exists in their implementation. General reasons include overestimation of care provided by other caregivers, lack of education and training particularly among students and residents, and lack of systematic practice organization such as electronic medical records that reinforce compliance. 18 Physician, institutional and cultural (specialty) attitudes should not be underestimated. For example, internists specializing in diabetes care in general hospitals in The
Netherlands were asked to indicate the perceived organizational and personal barriers to adherence to the diabetes guidelines. Ninety-one percent of the 120 specialist queried responded and identified cognitive, physician attitude, and social and organizational barriers to ncome countries, particularly in their rural areas. 17 Hence, underutilization of car ar rdi di iop op pro rote te tect ct ctiv iv ive e medication in patients with PAD is a conspicuous example of a more generalized failure to em mbr br brac ac ace e se se seco co cond dar ar ary y y preventive guidelines.
Cardio ova va asc c cul l lar ar p p pra ra ac ct ctic ic ice e gu gu uid id del elin ine es f fo or or sec con on nda a ary ry ry p pr r rev ve vent nt tio o on n ar are e d de desi si ign g gned ed d t t to o su supp pp por ort t t reported that the guidelines were too rigid, and 50% simply didn't like imposed activities. 19 Could it be that guidelines are too rigid and do not reflect the complexities of practice in the trenches? Evidence suggests otherwise. Treatment with a statin to lower LDL cholesterol < 100 gm/dl is a class 1 level B recommendation in PAD patients. Given that the majority of patients with PAD who are on a statin will still die of cardiovascular disease, an LDL of 100 mg/dl or even 70 mg/dl may be too high. Both the Reversal of Atherosclerosis and Aggressive
Lipid Lowering (REVERSAL) and the Pravastatin or Atorvastatin Evaluation and Infection
Therapy (PROVE IT) trial also support targeting LDL to 70 mg/dl in high risk patients to lower cardiovascular events. 20, 21 The "lower is better" hypothesis is supported by the Heart Protection Study (HPS) where evidence was provided that allocation to statin therapy in patients with PAD produced a 25% risk reduction irrespective of baseline cholesterol levels at entry into the study. 22 These results are relevant as a recent prospective cohort study of 225 patients undergoing lower extremity bypass had a mean LDL of 63.7 mg/dl (60.9 mg/dl for those on statin and 74.9 for those not on statin therapy at the time of surgery). 23 Thus a good number of these advanced PAD patients had LDL levels within current guidelines---even without being on a statin at the time of their leg surgery. Yet in the same cohort, high-sensitivity C-reactive protein (hs-CRP) levels were notably elevated, with a mean value of 12.0 mg/l (median 3.0 mg/l). This begins to get at the nature of the persistent gap in evidence for PAD, which may also be at play.
What are the most appropriate goals for statin therapy in the PAD patient? Is it LDL cholesterol, or should it be hs-CRP or a combination thereof? Unfortunately the evidence base supporting treatment targets specific to PAD remains quite thin, and clearly we need more high quality, Therapy (PROVE IT) trial also support targeting LDL to 70 mg/dl in high risk k p pat at atie ient nt nts s s to to to ower cardiovascular events. 20, 21 The "lower is better" hypothesis is supported by the Heart Pr rot ot otec ec ecti ti tion on n S S Stu tu tudy y y ( ( (H H HPS) where evidence was prov ov ovid d ded that allocat at tio i n n to to to s statin therapy in patients w with h h PAD pro odu du uce ce ed a a 25 5 5% % % ri ri risk sk sk r red ed edu uc uct ti io on n irr r res spec c cti iv ve of of f b ba a asel el e in ine ch chol ol le es este tero ro ol l le leve ve els ls ls a at t en en ntr t try y in n nto h he e e st st tud ud udy. y. y 22 22 T T The hes s se r res esu u ult ts ts a are e r rel el elev ev evan a ant t as as a a a a r r rec ec e en en ent t pr pr pro ospe pe pect ct ctiv iv ive e co co c h ho hort rt rt s stu Administrative datasets such as the Denmark cohort have limitations. There are no hemodynamic data on severity of PAD as assessed by ABI or other noninvasive testing. As the authors admit, ICD-10 codes most likely capture patients who are symptomatic, in a hospital setting, and are therefore more likely to be treated. Admittedly little data exists to guide us on secondary prevention in asymptomatic PAD patients but may be assumed that they would receive even less aggressive treatment. In fact, recent studies suggest that aspirin, the staple cost-effective drug of cardiovascular specialists, may be of no benefit in the asymptomatic PAD population. 24 There is no data available on either cholesterol levels or blood pressure in the Danish cohort, and we therefore cannot know if the non-medicated patients are already within current guidelines. There is also no provider data. It is well documented that disparities exists in knowledge and action gaps in the treatment of PAD between internal medicine, vascular surgeons, and cardiologists.
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The good news is that the gap between PAD and CAD is closing but we are not there yet.
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